NASDAQ:EMMA - Nasdaq -
2.77
-1.72 (-38.31%)
The current stock price of EMMA is 2.77 null. In the past month the price decreased by -30.75%.
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.
Emmaus Life Sciences Inc.
21250 Hawthorne Boulevard Suite 800
Torrance CA 90503
CEO: George C. Carpenter
Phone: 310-214-0065
The current stock price of EMMA is 2.77 null. The price decreased by -38.31% in the last trading session.
The exchange symbol of Emmaus Life Sciences Inc. is EMMA and it is listed on the Nasdaq exchange.
EMMA stock is listed on the Nasdaq exchange.
Emmaus Life Sciences Inc. (EMMA) has a market capitalization of 131.48M null. This makes EMMA a Micro Cap stock.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EMMA does not pay a dividend.
Emmaus Life Sciences Inc. (EMMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.16).
The outstanding short interest for Emmaus Life Sciences Inc. (EMMA) is 0.07% of its float. Check the ownership tab for more information on the EMMA short interest.
ChartMill assigns a fundamental rating of 3 / 10 to EMMA. EMMA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months EMMA reported a non-GAAP Earnings per Share(EPS) of -11.16. The EPS increased by 26.19% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -729.66% | ||
ROA | -220.74% | ||
ROE | -570.03% | ||
Debt/Equity | 0.37 |
ChartMill assigns a Buy % Consensus number of 100% to EMMA. The Buy consensus is the average rating of analysts ratings from 2 analysts.